BAY HARBOR ISLAND, FL--(Marketwired - Dec 16, 2015) - Biotech Products Services & Research, Inc. (OTCQB: BPSR) ("Biotech") is pleased to announce a commercial referral agreement has been signed with US Stem Cell Clinic of Sunrise, FL and Biotech's wholly owned subsidiary "Beyond Cells LLC". This new working relationship will extend significant benefits to Beyond Cells clients seeking effective alternative therapies. Our clientele will now have a direct pathway to the conveniently situated US Stem Cell Clinic in southern Florida for adipose stem cell and other advanced regenerative therapy treatments. The combination of comprehensive patient referral services by Beyond Cells and excellence in treatment by the US Stem Cell Clinic will act to ensure the best possible outcomes for all our patients' needs.

US Stem Cell Clinic works to improve the quality of life for patients by employing the latest stem cell treatments with proven, safe and effective results. Their procedures harness the body's own healing potential by isolating stem cells from one location of the body and relocating them to an area of disease, injury or inflammation to aid with restoration. Treatment procedures are all done on an outpatient basis using a minimally invasive surgical technique to isolate adult mesenchymal stem cells and immediately deliver those cells back to the patient where needed. The cells may be delivered as a joint injection, an IV, intrathecal or intramuscularly. The entire process takes less than 3 hours to complete in most cases.

The Beyond Cells team is now looking forward to collaborating extensively with US Stem Cell Clinic's Chief Science Officer Kristin Comella, a world renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapin's list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Ms. Comella has pioneered stem cell therapies from various sources including cord blood, bone marrow, muscle and adipose tissue, developing a wide range of regenerative techniques and products that have been successfully implemented into the clinical setting. Additionally, Ms. Comella led the team that gained the first ever FDA approval for a clinical trial using a combined cell and gene therapy product in the heart. Now, with the referral agreement between Beyond Cells LLC and US Stem Cell Clinic in place, our patients will have access to some of the finest modern stem cell treatments available today and we will also work together steadfastly to advance new developments in these vital treatments for the future.

About Biotech Products Services & Research, Inc.

Biotech Products Services & Research Inc. focuses on a lifestyle of health and wellness. Our vision is to be a vertically integrated company, which primarily provides a patient referral service for integrative cellular therapies. Biotech also markets cellular products to doctors and hospitals.

Biotech aims to be the leader in the industry of innovative cell-based therapeutic with our unique strategy, which will guide a future of customized disease management. Biotech also sells women's fashion products through its Ethan New York subsidiary as part of our vertically integrated health and wellness vision.

For more information investors can visit


The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Biotech Products Services & Research, Inc., plans and expectations. In this press release and related comments by Company management, words like "expect," "anticipate," "estimate," "goal" and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.

Management believes these forward-looking statements and the judgments upon which they are based to be reasonable, but they are not guarantees of future performance and involve numerous known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, achievements or financial position to be materially different from any expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially from the forward-looking statements are set forth in our Form 10-K and other filings with the SEC. Other information can be obtained at

Contact Information:

Biotech Products Services & Research, Inc.